{Reference Type}: Journal Article
{Title}: Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review.
{Author}: Matsumura K;Sugiura T;
{Journal}: Cardiovasc Ultrasound
{Volume}: 17
{Issue}: 1
{Year}: Nov 2019 13
{Factor}: 2.263
{DOI}: 10.1186/s12947-019-0177-8
{Abstract}: A high incidence of left ventricular diastolic dysfunction and increased risk of cardiovascular events have been reported in patients with diabetes mellitus. Sodium glucose cotransporter 2 (SGLT2) inhibitors selectively inhibit kidney glucose and sodium reabsorption, and cardiovascular benefits of SGLT2 inhibitors beyond other antidiabetic drugs have been reported in type 2 diabetes mellitus (T2DM) clinical trials. However, underlying mechanisms contributing to the improvement of cardiovascular outcomes have not been clearly identified. In this review, likely mechanisms of SGLT2 inhibitors contributing to a favorable cardiovascular outcomes are discussed based on experimental and clinical studies on cardiac function.